Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 13

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---

 Recent Accounting Pronouncements The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management’s opinion will not have a material impact on the Company’s present or future consolidated financial statements.

Note 3 - Inventory As of June 30, 2025 and December 31, 2024, inventory consisted of raw materials, subassemblies to be used in the assembly of TAEUS systems, and finished goods. As of June 30, 2025, the Company had no orders pending for the sale of a TAEUS system. As of June 30, 2025 and December 31, 2024, the Company had recorded reserves of $0 and $2,525,179, respectively. As of June 30, 2025 and December 31, 2024, the Company had inventory valued at $0.

Note 4 - Fixed Assets         As of June 30, 2025 and December 31, 2024, fixed assets consisted of the following:       June 30,  December 31,   2025  2024 Property, leasehold and capitalized software $597,234  $579,954 TAEUS development and testing  125,151   125,151 Accumulated depreciation  (658,966)  (635,824)Fixed assets, net $63,419  $69,281  Depreciation expense for the six months ended June 30, 2025 and June 30, 2024 was $23,142 and $23,993, respectively.

Note 5 - Accounts Payable and Accrued Liabilities         As of June 30, 2025 and December 31, 2024, current liabilities consisted of the following:       June 30,  December 31,   2025  2024 Accounts payable $281,992  $269,683 Payroll accrual  110,677   63,140 Accrued employee benefits  5,750   5,750 Accrued expenses  50,000   169,720 Total $448,419  $508,293 

Note 6 - Bank Loans Toronto-D